LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Oral bioavailability enhancement of flubendazole by developing nanofibrous solid dosage forms.

    Vigh, Tamás / Démuth, Balázs / Balogh, Attila / Galata, Dorián L / Van Assche, Ivo / Mackie, Claire / Vialpando, Monica / Van Hove, Ben / Psathas, Petros / Borbás, Enikő / Pataki, Hajnalka / Boeykens, Peter / Marosi, György / Verreck, Geert / Nagy, Zsombor K

    Drug development and industrial pharmacy

    2017  Volume 43, Issue 7, Page(s) 1126–1133

    Abstract: The bioavailability of the anthelminthic flubendazole was remarkably enhanced in comparison with the pure crystalline drug by developing completely amorphous electrospun nanofibres with a matrix consisting of hydroxypropyl-β-cyclodextrin and ... ...

    Abstract The bioavailability of the anthelminthic flubendazole was remarkably enhanced in comparison with the pure crystalline drug by developing completely amorphous electrospun nanofibres with a matrix consisting of hydroxypropyl-β-cyclodextrin and polyvinylpyrrolidone. The thus produced formulations can potentially be active against macrofilariae parasites causing tropical diseases, for example, river blindness and elephantiasis, which affect altogether more than a hundred million people worldwide. The bioavailability enhancement was based on the considerably improved dissolution. The release of a dose of 40 mg could be achieved within 15 min. Accordingly, administration of the nanofibrous system ensured an increased plasma concentration profile in rats in contrast to the practically non-absorbable crystalline flubendazole. Furthermore, easy-to-grind fibers could be developed, which enabled compression of easily administrable immediate release tablets.
    MeSH term(s) 2-Hydroxypropyl-beta-cyclodextrin ; Administration, Oral ; Animals ; Biological Availability ; Chemistry, Pharmaceutical ; Crystallization ; Mebendazole/administration & dosage ; Mebendazole/analogs & derivatives ; Mebendazole/chemistry ; Nanofibers/chemistry ; Povidone/chemistry ; Rats ; Tablets/chemistry ; beta-Cyclodextrins/chemistry
    Chemical Substances Tablets ; beta-Cyclodextrins ; 2-Hydroxypropyl-beta-cyclodextrin (1I96OHX6EK) ; Mebendazole (81G6I5V05I) ; Povidone (FZ989GH94E) ; flubendazole (R8M46911LR)
    Language English
    Publishing date 2017-07
    Publishing country England
    Document type Journal Article
    ZDB-ID 751874-2
    ISSN 1520-5762 ; 0363-9045
    ISSN (online) 1520-5762
    ISSN 0363-9045
    DOI 10.1080/03639045.2017.1298121
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Evaluation of Three Amorphous Drug Delivery Technologies to Improve the Oral Absorption of Flubendazole.

    Vialpando, Monica / Smulders, Stefanie / Bone, Scott / Jager, Casey / Vodak, David / Van Speybroeck, Michiel / Verheyen, Loes / Backx, Katrien / Boeykens, Peter / Brewster, Marcus E / Ceulemans, Jens / Novoa de Armas, Hector / Van Geel, Katrien / Kesselaers, Emma / Hillewaert, Vera / Lachau-Durand, Sophie / Meurs, Greet / Psathas, Petros / Van Hove, Ben /
    Verreck, Geert / Voets, Marieke / Weuts, Ilse / Mackie, Claire

    Journal of pharmaceutical sciences

    2016  Volume 105, Issue 9, Page(s) 2782–2793

    Abstract: This study investigates 3 amorphous technologies to improve the dissolution rate and oral bioavailability of flubendazole (FLU). The selected approaches are (1) a standard spray-dried dispersion with hydroxypropylmethylcellulose (HPMC) E5 or ... ...

    Abstract This study investigates 3 amorphous technologies to improve the dissolution rate and oral bioavailability of flubendazole (FLU). The selected approaches are (1) a standard spray-dried dispersion with hydroxypropylmethylcellulose (HPMC) E5 or polyvinylpyrrolidone-vinyl acetate 64, both with Vitamin E d-α-tocopheryl polyethylene glycol succinate; (2) a modified process spray-dried dispersion (MPSDD) with either HPMC E3 or hydroxypropylmethylcellulose acetate succinate (HPMCAS-M); and (3) confining FLU in ordered mesoporous silica (OMS). The physicochemical stability and in vitro release of optimized formulations were evaluated following 2 weeks of open conditions at 25°C/60% relative humidity (RH) and 40°C/75% RH. All formulations remained amorphous at 25°C/60% RH. Only the MPSDD formulation containing HPMCAS-M and 3/7 (wt./wt.) FLU/OMS did not crystallize following 40°C/75% RH exposure. The OMS and MPSDD formulations contained the lowest and highest amount of hydrolyzed degradant, respectively. All formulations were dosed to rats at 20 mg/kg in suspension. One FLU/OMS formulation was also dosed as a capsule blend. Plasma concentration profiles were determined following a single dose. In vivo findings show that the OMS capsule and suspension resulted in the overall highest area under the curve and Cmax values, respectively. These results cross-evaluate various amorphous formulations and provide a link to enhanced biopharmaceutical performance.
    Language English
    Publishing date 2016-09
    Publishing country United States
    Document type Journal Article
    ZDB-ID 3151-3
    ISSN 1520-6017 ; 0022-3549
    ISSN (online) 1520-6017
    ISSN 0022-3549
    DOI 10.1016/j.xphs.2016.03.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top